Business Context and Reporting Period
This Form 8-K was filed by Vanda Pharmaceuticals Inc. on October 17, 2017, reporting a significant commercial development regarding its product HETLIOZ (tasimelteon) in Germany.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed is the agreed-upon ex-factory price for HETLIOZ in Germany, set at approximately EUR 69,000 per year per patient.
Material Changes
The primary material event is the resolution of pricing negotiations for HETLIOZ in Germany following an Arbitration Board decision under the German Pharmaceuticals Market Reorganization Act (AMNOG). This agreement establishes a legally binding price for the treatment of totally blind individuals with Non-24-Hour Sleep-Wake Disorder.
Guidance, Outlook, and Management Commentary
The filing confirms that the pricing agreement is effective retroactively to August 1, 2017. Management notes that the outcome of the Arbitration Board is legally binding, removing uncertainty regarding the reimbursement price in this specific market segment.
Investor Verification Checklist
- Verify the commercial impact of the EUR 69,000 annual price point on projected German revenue.
- Confirm the volume of eligible patients (totally blind individuals with Non-24-Hour Sleep-Wake Disorder) in Germany.
- Review subsequent filings for actual sales data post-August 1, 2017, to assess uptake.
- Check for any additional regulatory or pricing hurdles in other European markets.